ESR1 and breast carcinoma: Mutations or amplifications in the ERBB2 gene are observed in approximately 5% and 2% of the ER+/HER2− relapsed breast cancer population, respectively [22], while nearly half of these cases exhibit increased activity of the PI3K/Akt pathway [23].